SINOVAC BIOTECH LTD
SVANasdaqHealthcare · Pharmaceutical Preparations · B9 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Signs
● 1 severe● 0 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 20-Fmissed a reporting deadline ↗Apr 30, 2026
- NT 20-Fmissed a reporting deadline ↗Apr 29, 2025
- NT 20-F/Amissed a reporting deadline ↗May 8, 2018
- NT 20-Fmissed a reporting deadline ↗Apr 30, 2018
- NT 20-Fmissed a reporting deadline ↗May 1, 2017
- NT 20-Fmissed a reporting deadline ↗Jun 30, 2006
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2025-11-30Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)
- Phase 1/2Active Not Recruitingreadout ~2025-12-19Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial
- Phase 2Not Yet Recruitingreadout ~2026-01-15Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)
- Phase 3Recruitingreadout ~2026-03Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women
- Phase 4Recruitingreadout ~2026-04-11Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations
- Phase 1/2Recruitingreadout ~2026-05-31Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine
- Phase 1Not Yet Recruitingreadout ~2026-06-30Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine
- Phase 4Recruitingreadout ~2026-09-08Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ifg Investments Services Inc10% owner | Nov 4, 2003 | Sell | 6.0M | $0.03 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 82,747 | 1000.0 | -0.0% |
| Apr 30, 2026 | 82,758 | 1000.0 | 0.0% |
| Apr 15, 2026 | 82,758 | 1000.0 | 0.0% |
| Mar 31, 2026 | 82,758 | 1000.0 | 0.0% |
| Mar 13, 2026 | 82,758 | 1000.0 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recentEvents the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 6-KREPORT OF FOREIGN PRIVATE ISSUERMay 29, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERMay 21, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERMay 8, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERMay 7, 2026
- NT 20-FNOTIFICATION OF LATE FILINGApr 30, 2026
- 20-FApr 30, 2026
- 3Apr 17, 2026
- 3Mar 18, 2026
- 3Mar 18, 2026
- 3Mar 18, 2026
- 3Mar 18, 2026
- 3Mar 18, 2026
- 3Mar 18, 2026
- 3Mar 18, 2026
- 3Mar 18, 2026